Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D015536:Down-Regulation; D005419:Flavonoids / Q000494:pharmacology*; D015870:Gene Expression; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D019169:Jurkat Cells; D010880:Piperidines / Q000494:pharmacology*; D020298:U937 Cells
D000970:Antineoplastic Agents; D002087:Butyrates; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D005419:Flavonoids; D056572:Histone Deacetylase Inhibitors; D010880:Piperidines; C077990:alvocidib; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases